The world market for prescription hematology drugs was worth almost $6 billion in 1992, according to a new report published by Datamonitor. The largest segment of this market is for plasma factors, which accounts for around $2 billion of the total.
The most recent drugs to enter the hematology market are recombinant products, heralded by the launch of recombinant erythropoetin (EPO), G-CSF and granulocyte-macrophage colony stimulating factor in 1989. These have revolutionized the treatment of cancer and other chronic diseases such as AIDS. Recombinant drugs now dominate the blood cell stimulant sector, and are a valuable area for pharmaceutical companies. For example, Amgen's sales in 1992 increased by more than 60% on the back of revenues from Epogen and Neupogen.